Detalhe da pesquisa
1.
PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress.
Nature
; 566(7743): 264-269, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30700906
2.
Characterization of a robust mouse model of heart failure with preserved ejection fraction.
Am J Physiol Heart Circ Physiol
; 325(2): H203-H231, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37204871
3.
PKG1α Cysteine-42 Redox State Controls mTORC1 Activation in Pathological Cardiac Hypertrophy.
Circ Res
; 127(4): 522-533, 2020 07 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-32393148
4.
Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension.
Circulation
; 137(22): 2360-2370, 2018 05 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29352073
5.
CHIP phosphorylation by protein kinase G enhances protein quality control and attenuates cardiac ischemic injury.
Nat Commun
; 11(1): 5237, 2020 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33082318
6.
Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation.
Circ Heart Fail
; 11(3): e004740, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545395
7.
Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.
JCI Insight
; 3(15)2018 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30089721
8.
Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis.
Nat Commun
; 9(1): 5230, 2018 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30531796